期刊
INTERNAL MEDICINE
卷 51, 期 15, 页码 2041-2044出版社
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.51.7592
关键词
dipeptidyl peptidase (DPP)-4 inhibitor; rheumatoid arthritis; human leukocyte antigen (HLA)
A dipeptidyl peptidase (DPP)-4 inhibitor, commonly used to treat patients with type 2 diabetes, has caused concern because of immune system side effects. We report a 48-year-old woman with type 2 diabetes who was diagnosed with rheumatoid arthritis (RA) after continued polyarthritis and an increase in rheumatoid factor up to 86 IU/mL after three months of treatment with sitagliptin, a DPP-4 inhibitor. The shared epitope (SE)-containing human leukocyte antigen (HLA)-DRB1 alleles, which are important predisposing factors for RA, were positive. RA might have been triggered by sitagliptin due to a predisposing condition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据